molecules of the month


allosteric mutant IDH1/2 dual inhibitor

oral, brain penetrant, completed Ph. I in HV

from SBDD of prior mIDH inhibitor

ACS Med. Chem. Lett., 2020, 11, 101-107

Agios Pharmaceuticals, Cambridge, MA

1 min read

AG-881 (vorasidenib) (Agios oral brain penetrant allosteric mutant IDH1/2 dual inhibitor clinical candidate)

request a trial

Drug Hunter is commited to helping industry innovators make informed decisions. Premium members have access to our library of the latest stories in science, written by scientists.

Request a trial to access insights powering the pros in our industry.

already a member? log in: